# About Ascent Peptides — A Growth Hormone Axis Research Digest

> About Ascent Peptides: an independent literature digest on three Growth Hormone Axis research peptides — CJC-1295, Sermorelin and Tesamorelin. How it is compiled, and what it is not.

An independent, citation-anchored reading of the GH-axis research peptide literature. Not a vendor. Not a clinic. Not medical advice.

## What Ascent Peptides is

Ascent Peptides is an independent editorial digest covering the published research on three peptides studied for the **growth hormone axis**: CJC-1295, Sermorelin and Tesamorelin, with CJC-1295 as the lead. The site exists to make a scattered and frequently overstated literature legible — to tell a reader, in plain language and with citations, what each GHRH analog was actually studied for, in which populations, and how far that evidence reaches.

The organizing frame is the GH-axis secretagogue class: three compounds that share a receptor target (the pituitary GHRH receptor) and a basic mechanism (upstream stimulation of the GH/IGF-1 axis), but diverge sharply in their structural durability strategies, their half-lives, and their depth of human evidence. Reading them as a group reveals both what the class can do in principle and where each individual compound's evidence actually ends. Each compound has its own page; a comparison page lines them up side by side; and a single shared references list aggregates every source.

## How it is compiled

Three principles govern what appears on this site.

*First, everything is anchored to the peer-reviewed literature.* Every research claim is tied to a numbered citation — PubMed-indexed journal articles, reviews and official monographs — collected on the [references page](/references). Where a finding comes from a review or editorial rather than a primary study, the review or editorial is cited as such, and its status as secondary commentary is noted.

*Second, the evidence is described at its true strength.* Doses and outcomes are described in the species and context in which they were studied — "raised mean GH 2- to 10-fold in healthy adults" or "reduced visceral fat in HIV-infected adults on antiretroviral therapy" — never scaled to general recommendations. Where an approved indication exists, it is described in its approved terms; off-label questions are framed as research questions. Where editorial opinion explicitly cautions against a use, that caution appears prominently, not as a footnote.

*Third, the three pages are cross-referenced.* Because the same receptor, the same GH/IGF-1 axis, and the same DPP-IV stability problem recur across all three compounds, the pages link to one another so a reader can follow a design choice or an evidence gap from one analog to the next.

## What it is not

Ascent Peptides is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person.

The peptides discussed here are research compounds or, in the case of tesamorelin, a prescription drug approved for a specific indication. None is an over-the-counter supplement; several are explicitly prohibited in sport. Readers interested in conditions described in the underlying research should consult a licensed clinician operating within their own jurisdiction, working with regulated, evidence-based options. This site offers a careful reading of the research literature — nothing more, and nothing it pretends to be.

---

A literature digest tracing three GHRH analogs through the peer-reviewed record — mechanism, evidence, and caution, but never a dose or a product.